Association of Heart Failure Patients With and Without Sacubitril–Valsartan Use With Incident Cancer Risk

Abstract This study was to evaluate the association between heart failure (HF) patients with and without sacubitril–valsartan use with incident cancer risk. This study consisted of 18,072 patients receiving sacubitril–valsartan and 18,072 control group participants. In the Fine and Gray model, which extends the standard Cox proportional hazards regression model, we estimated the relative risk of developing cancer between the sacubitril–valsartan cohort and the non–sacubitril–valsartan cohort by using subhazard ratios (SHRs) and 95% confidence intervals (CIs). The incidence rates of cancer were 12.02 per 1000 person-years for the sacubitril–valsartan cohort and 23.31 per 1000 person-years for the non–sacubitril–valsartan cohort. Patients receiving sacubitril–valsartan had a significantly lower risk of developing cancer with an adjusted SHR of 0.60 (0.51, 0.71). Sacubitril–valsartan users were less to be associated with the development of cancer.